Trials / Completed
CompletedNCT05925686
Tramadol to Improve Its Detection in Biological Matrices in Anti-doping Controls
Tramadol Administered Orally to Healthy Subjects for the Improvement of Its Detection in Biological Matrices in the Context of Anti-Doping Control
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Parc de Salut Mar · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers will be administered with the objective to evaluate urine and blood concentrations in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tramadol. | Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers. |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2023-10-11
- Completion
- 2023-10-17
- First posted
- 2023-06-29
- Last updated
- 2023-11-03
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05925686. Inclusion in this directory is not an endorsement.